Effect of Long-Acting Testosterone Treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure. A Double-Blind, Placebo-Controlled, Randomized Study

Research output: Contribution to journalArticle

305 Citations (Scopus)

Abstract

Objectives: This study investigated the effect of a 12-week long-acting testosterone administration on maximal exercise capacity, ventilatory efficiency, muscle strength, insulin resistance, and baroreflex sensitivity (BRS) in elderly patients with chronic heart failure (CHF). Background: CHF is characterized by a metabolic shift favoring catabolism and impairment in skeletal muscle bulk and function that could be involved in the pathophysiology of heart failure. Methods: Seventy elderly patients with stable CHF-median age 70 years, ejection fraction 31.8 ± 7%-were randomly assigned to receive testosterone (n = 35, intramuscular injection every 6 weeks) or placebo (n = 35), both on top of optimal medical therapy. At baseline and at the end of the study, all patients underwent echocardiogram, cardiopulmonary exercise test, 6-min walk test (6MWT), quadriceps maximal voluntary contraction (MVC), and isokinetic strength (peak torque) and BRS assessment (sequences technique). Results: Baseline peak oxygen consumption (VO2) and quadriceps isometric strength showed a direct relation with serum testosterone concentration. Peak VO2 significantly improved in testosterone but was unchanged in placebo. Insulin sensitivity was significantly improved in testosterone. The MVC and peak torque significantly increased in testosterone but not in placebo. The BRS significantly improved in testosterone but not in placebo. Increase in testosterone levels was significantly related to improvement in peak VO2 and MVC. There were no significant changes in left ventricular function either in testosterone or placebo. Conclusions: These results suggest that long-acting testosterone therapy improves exercise capacity, muscle strength, glucose metabolism, and BRS in men with moderately severe CHF. Testosterone benefits seem to be mediated by metabolic and peripheral effects.

Original languageEnglish
Pages (from-to)919-927
Number of pages9
JournalJournal of the American College of Cardiology
Volume54
Issue number10
DOIs
Publication statusPublished - Sep 1 2009

Fingerprint

Baroreflex
Insulin Resistance
Testosterone
Skeletal Muscle
Heart Failure
Placebos
Exercise
Therapeutics
Torque
Muscle Strength
Exercise Therapy
Respiratory Muscles
Intramuscular Injections
Exercise Test
Left Ventricular Function
Oxygen Consumption
Glucose

Keywords

  • baroreflex sensitivity
  • congestive heart failure
  • exercise capacity
  • glucose metabolism
  • testosterone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{4ed15fda80d54388bfed0c04d83b54fc,
title = "Effect of Long-Acting Testosterone Treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure. A Double-Blind, Placebo-Controlled, Randomized Study",
abstract = "Objectives: This study investigated the effect of a 12-week long-acting testosterone administration on maximal exercise capacity, ventilatory efficiency, muscle strength, insulin resistance, and baroreflex sensitivity (BRS) in elderly patients with chronic heart failure (CHF). Background: CHF is characterized by a metabolic shift favoring catabolism and impairment in skeletal muscle bulk and function that could be involved in the pathophysiology of heart failure. Methods: Seventy elderly patients with stable CHF-median age 70 years, ejection fraction 31.8 ± 7{\%}-were randomly assigned to receive testosterone (n = 35, intramuscular injection every 6 weeks) or placebo (n = 35), both on top of optimal medical therapy. At baseline and at the end of the study, all patients underwent echocardiogram, cardiopulmonary exercise test, 6-min walk test (6MWT), quadriceps maximal voluntary contraction (MVC), and isokinetic strength (peak torque) and BRS assessment (sequences technique). Results: Baseline peak oxygen consumption (VO2) and quadriceps isometric strength showed a direct relation with serum testosterone concentration. Peak VO2 significantly improved in testosterone but was unchanged in placebo. Insulin sensitivity was significantly improved in testosterone. The MVC and peak torque significantly increased in testosterone but not in placebo. The BRS significantly improved in testosterone but not in placebo. Increase in testosterone levels was significantly related to improvement in peak VO2 and MVC. There were no significant changes in left ventricular function either in testosterone or placebo. Conclusions: These results suggest that long-acting testosterone therapy improves exercise capacity, muscle strength, glucose metabolism, and BRS in men with moderately severe CHF. Testosterone benefits seem to be mediated by metabolic and peripheral effects.",
keywords = "baroreflex sensitivity, congestive heart failure, exercise capacity, glucose metabolism, testosterone",
author = "Giuseppe Caminiti and Maurizio Volterrani and Ferdinando Iellamo and Giuseppe Marazzi and Rosalba Massaro and Marco Miceli and Caterina Mammi and Massimo Piepoli and Massimo Fini and Rosano, {G. M C}",
year = "2009",
month = "9",
day = "1",
doi = "10.1016/j.jacc.2009.04.078",
language = "English",
volume = "54",
pages = "919--927",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Effect of Long-Acting Testosterone Treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure. A Double-Blind, Placebo-Controlled, Randomized Study

AU - Caminiti, Giuseppe

AU - Volterrani, Maurizio

AU - Iellamo, Ferdinando

AU - Marazzi, Giuseppe

AU - Massaro, Rosalba

AU - Miceli, Marco

AU - Mammi, Caterina

AU - Piepoli, Massimo

AU - Fini, Massimo

AU - Rosano, G. M C

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Objectives: This study investigated the effect of a 12-week long-acting testosterone administration on maximal exercise capacity, ventilatory efficiency, muscle strength, insulin resistance, and baroreflex sensitivity (BRS) in elderly patients with chronic heart failure (CHF). Background: CHF is characterized by a metabolic shift favoring catabolism and impairment in skeletal muscle bulk and function that could be involved in the pathophysiology of heart failure. Methods: Seventy elderly patients with stable CHF-median age 70 years, ejection fraction 31.8 ± 7%-were randomly assigned to receive testosterone (n = 35, intramuscular injection every 6 weeks) or placebo (n = 35), both on top of optimal medical therapy. At baseline and at the end of the study, all patients underwent echocardiogram, cardiopulmonary exercise test, 6-min walk test (6MWT), quadriceps maximal voluntary contraction (MVC), and isokinetic strength (peak torque) and BRS assessment (sequences technique). Results: Baseline peak oxygen consumption (VO2) and quadriceps isometric strength showed a direct relation with serum testosterone concentration. Peak VO2 significantly improved in testosterone but was unchanged in placebo. Insulin sensitivity was significantly improved in testosterone. The MVC and peak torque significantly increased in testosterone but not in placebo. The BRS significantly improved in testosterone but not in placebo. Increase in testosterone levels was significantly related to improvement in peak VO2 and MVC. There were no significant changes in left ventricular function either in testosterone or placebo. Conclusions: These results suggest that long-acting testosterone therapy improves exercise capacity, muscle strength, glucose metabolism, and BRS in men with moderately severe CHF. Testosterone benefits seem to be mediated by metabolic and peripheral effects.

AB - Objectives: This study investigated the effect of a 12-week long-acting testosterone administration on maximal exercise capacity, ventilatory efficiency, muscle strength, insulin resistance, and baroreflex sensitivity (BRS) in elderly patients with chronic heart failure (CHF). Background: CHF is characterized by a metabolic shift favoring catabolism and impairment in skeletal muscle bulk and function that could be involved in the pathophysiology of heart failure. Methods: Seventy elderly patients with stable CHF-median age 70 years, ejection fraction 31.8 ± 7%-were randomly assigned to receive testosterone (n = 35, intramuscular injection every 6 weeks) or placebo (n = 35), both on top of optimal medical therapy. At baseline and at the end of the study, all patients underwent echocardiogram, cardiopulmonary exercise test, 6-min walk test (6MWT), quadriceps maximal voluntary contraction (MVC), and isokinetic strength (peak torque) and BRS assessment (sequences technique). Results: Baseline peak oxygen consumption (VO2) and quadriceps isometric strength showed a direct relation with serum testosterone concentration. Peak VO2 significantly improved in testosterone but was unchanged in placebo. Insulin sensitivity was significantly improved in testosterone. The MVC and peak torque significantly increased in testosterone but not in placebo. The BRS significantly improved in testosterone but not in placebo. Increase in testosterone levels was significantly related to improvement in peak VO2 and MVC. There were no significant changes in left ventricular function either in testosterone or placebo. Conclusions: These results suggest that long-acting testosterone therapy improves exercise capacity, muscle strength, glucose metabolism, and BRS in men with moderately severe CHF. Testosterone benefits seem to be mediated by metabolic and peripheral effects.

KW - baroreflex sensitivity

KW - congestive heart failure

KW - exercise capacity

KW - glucose metabolism

KW - testosterone

UR - http://www.scopus.com/inward/record.url?scp=68949172537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949172537&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2009.04.078

DO - 10.1016/j.jacc.2009.04.078

M3 - Article

C2 - 19712802

AN - SCOPUS:68949172537

VL - 54

SP - 919

EP - 927

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 10

ER -